메뉴 건너뛰기




Volumn 14, Issue 10, 2008, Pages 990-1000

Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4

Author keywords

Cytochrome P450 3A4; Drug development; Drug drug interactions; Mechanism based inhibition; Toxicity

Indexed keywords

ALFENTANIL; ALPRAZOLAM; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; ISONIAZID; KETOCONAZOLE; METHYLPREDNISOLONE; MEVINOLIN; MIBEFRADIL; MIDAZOLAM; NIFEDIPINE; PHENYTOIN; PIMOZIDE; QUINIDINE; RIFABUTIN; RISPERIDONE; RITONAVIR; SIMVASTATIN; TACROLIMUS; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

EID: 44449112267     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784139738     Document Type: Review
Times cited : (44)

References (156)
  • 2
    • 0035135258 scopus 로고    scopus 로고
    • cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
    • Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386-92.
    • (2001) Mol Pharmacol , vol.59 , pp. 386-392
    • Domanski, T.L.1    Finta, C.2    Halpert, J.R.3    Zaphiropoulos, P.G.4
  • 3
    • 0028237729 scopus 로고
    • Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
    • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengench FP. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
    • (1994) J Pharmacol Exp Ther , vol.270 , pp. 414-423
    • Shimada, T.1    Yamazaki, H.2    Mimura, M.3    Inui, Y.4    Guengench, F.P.5
  • 4
    • 0030834058 scopus 로고    scopus 로고
    • Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
    • Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug. Metab Rev 1997; 29: 413-580.
    • Drug. Metab Rev 1997
    • Rendic, S.1    Di Carlo, F.J.2
  • 5
    • 0028114619 scopus 로고
    • Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
    • Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-56.
    • (1994) J Pharmacol Exp Ther , vol.271 , pp. 549-556
    • Thummel, K.E.1    Shen, D.D.2    Podoll, T.D.3    Kunze, K.L.4    Trager, W.F.5    Hartwell, P.S.6
  • 6
    • 2342448026 scopus 로고    scopus 로고
    • Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver
    • Watanabe M, Kumai T, Matsumoto N, Tanaka M, Suzuki S, Satoh T, et al. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J Pharmacol Sci 2004; 94: 459-62.
    • (2004) J Pharmacol Sci , vol.94 , pp. 459-462
    • Watanabe, M.1    Kumai, T.2    Matsumoto, N.3    Tanaka, M.4    Suzuki, S.5    Satoh, T.6
  • 7
    • 1542376174 scopus 로고    scopus 로고
    • Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens
    • von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 172-183
    • von Richter, O.1    Burk, O.2    Fromm, M.F.3    Thon, K.P.4    Eichelbaum, M.5    Kivisto, K.T.6
  • 8
    • 0036515846 scopus 로고    scopus 로고
    • Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man
    • Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32: 165-206.
    • (2002) Xenobiotica , vol.32 , pp. 165-206
    • Gibson, G.G.1    Plant, N.J.2    Swales, K.E.3    Ayrton, A.4    El-Sankary, W.5
  • 9
    • 0036223831 scopus 로고    scopus 로고
    • Summary of information on human CYP enzymes: Human P450 metabolism data
    • Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
    • (2002) Drug Metab Rev , vol.34 , pp. 83-448
    • Rendic, S.1
  • 10
    • 0032924934 scopus 로고    scopus 로고
    • Cytochrome P-450 3A4: Regulation and role in drug metabolism
    • Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
    • (1999) Annu Rev Pharmacol Toxicol , vol.39 , pp. 1-17
    • Guengerich, F.P.1
  • 13
    • 0031819080 scopus 로고    scopus 로고
    • Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A
    • Voorman RL, Maio SK Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26: 631-9.
    • (1998) Drug Metab Dispos , vol.26 , pp. 631-639
    • Voorman, R.L.1    Maio, S.K.2    Hauer, M.J.3    Sanders, P.E.4    Payne, N.A.5    Ackland, M.J.6
  • 15
    • 0036196318 scopus 로고    scopus 로고
    • Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein
    • Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 2002; 301: 160-7.
    • (2002) J Pharmacol Exp Ther , vol.301 , pp. 160-167
    • Lin, H.L.1    Kent, U.M.2    Hollenberg, P.F.3
  • 16
    • 0036178095 scopus 로고    scopus 로고
    • Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation
    • Khan KK, He YQ, Domanski TL, Halpert JR. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 2002; 61: 495-506.
    • (2002) Mol Pharmacol , vol.61 , pp. 495-506
    • Khan, K.K.1    He, Y.Q.2    Domanski, T.L.3    Halpert, J.R.4
  • 17
    • 27244462157 scopus 로고    scopus 로고
    • Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains
    • Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001; 391: 49-55.
    • (2001) Arch Biochem Biophys , vol.391 , pp. 49-55
    • Schrag, M.L.1    Wienkers, L.C.2
  • 18
    • 0026346377 scopus 로고
    • Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds
    • Franklin MR. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 1991; 206: 559-73.
    • (1991) Methods Enzymol , vol.206 , pp. 559-573
    • Franklin, M.R.1
  • 19
    • 0036259952 scopus 로고    scopus 로고
    • The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9
    • Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002; 30: 709-15.
    • (2002) Drug Metab Dispos , vol.30 , pp. 709-715
    • Kent, U.M.1    Aviram, M.2    Rosenblat, M.3    Hollenberg, P.F.4
  • 20
    • 0344765487 scopus 로고    scopus 로고
    • Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
    • Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26: 609-16.
    • (1998) Drug Metab Dispos , vol.26 , pp. 609-616
    • Lillibridge, J.H.1    Liang, B.H.2    Kerr, B.M.3    Webber, S.4    Quart, B.5    Shetty, B.V.6
  • 21
    • 44449085280 scopus 로고    scopus 로고
    • Ortiz de Montellano PR, Correia MA. In Cytochrome P450: Structure, Mechanism and Biochemistry, PR Ortiz de Montellano, ed.; Plenum Press: New York, 1995; pp. 305-66.
    • Ortiz de Montellano PR, Correia MA. In Cytochrome P450: Structure, Mechanism and Biochemistry, PR Ortiz de Montellano, ed.; Plenum Press: New York, 1995; pp. 305-66.
  • 27
    • 4644308675 scopus 로고    scopus 로고
    • Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
    • Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5: 415-42.
    • (2004) Curr Drug Metab , vol.5 , pp. 415-442
    • Zhou, S.1    Chan, E.2    Lim, L.Y.3    Boelsterli, U.A.4    Li, S.C.5    Wang, J.6
  • 28
    • 0025236599 scopus 로고
    • Metabolite inhibition of parent drug biotransformation. Studies of diltiazem
    • Tsao S-C, Dickinson TH, Abernethy DR. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. Drug Metab Dispos 1990; 18: 180-2.
    • (1990) Drug Metab Dispos , vol.18 , pp. 180-182
    • Tsao, S.-C.1    Dickinson, T.H.2    Abernethy, D.R.3
  • 31
    • 0033026601 scopus 로고    scopus 로고
    • Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
    • Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999; 47: 291-8.
    • (1999) Br J Clin Pharmacol , vol.47 , pp. 291-298
    • Prueksaritanont, T.1    Ma, B.2    Tang, C.3    Meng, Y.4    Assang, C.5    Lu, P.6
  • 32
    • 0033972441 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    • Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
    • (2000) Clin Pharmacokinet , vol.38 , pp. 41-57
    • Dresser, G.K.1    Spence, J.D.2    Bailey, D.G.3
  • 34
    • 0033924849 scopus 로고    scopus 로고
    • Drug interactions with cisapride: Clinical implications
    • Michalets EL, Williams CR. Drug interactions with cisapride: Clinical implications. Clin Pharmacokinet 2000; 39: 49-75.
    • (2000) Clin Pharmacokinet , vol.39 , pp. 49-75
    • Michalets, E.L.1    Williams, C.R.2
  • 35
    • 0026671408 scopus 로고
    • Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
    • Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-8.
    • (1992) Clin Pharmacol Ther , vol.52 , pp. 231-238
    • Honig, P.K.1    Woosley, R.L.2    Zamani, K.3    Conner, D.P.4    Cantilena, L.R.5
  • 36
    • 0027996327 scopus 로고
    • Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals
    • Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22: 849-57.
    • (1994) Drug Metab Dispos , vol.22 , pp. 849-857
    • Jurima-Romet, M.1    Crawford, K.2    Cyr, T.3    Inaba, T.4
  • 37
    • 0027468346 scopus 로고
    • Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
    • Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
    • (1993) JAMA , vol.269 , pp. 1513-1518
    • Honig, P.K.1    Wortham, D.C.2    Zamani, K.3    Conner, D.P.4    Mullin, J.C.5    Cantilena, L.R.6
  • 38
    • 0036291921 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
    • Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 343-370
    • Williams, D.1    Feely, J.2
  • 39
    • 0034986591 scopus 로고    scopus 로고
    • Cardiovascular drug-drug interactions
    • Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001; 19: 215-34.
    • (2001) Cardiol Clin , vol.19 , pp. 215-234
    • Anderson, J.R.1    Nawarskas, J.J.2
  • 40
    • 0036019860 scopus 로고    scopus 로고
    • Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
    • Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002; 14: 178-88.
    • (2002) Int J Impot Res , vol.14 , pp. 178-188
    • Simonsen, U.1
  • 42
    • 0029815563 scopus 로고    scopus 로고
    • Clinically significant pharmacokinetic drug interactions with carbamazepine. An update
    • Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198-214.
    • (1996) Clin Pharmacokinet , vol.31 , pp. 198-214
    • Spina, E.1    Pisani, F.2    Perucca, E.3
  • 43
    • 0029011397 scopus 로고
    • The interaction of the calcium antagonist RO 40-5967 with digoxin
    • Siepmann M, Kleinbloesem C, Kirch W. The interaction of the calcium antagonist RO 40-5967 with digoxin. Br J Clin Pharmacol 1995; 39: 491-6.
    • (1995) Br J Clin Pharmacol , vol.39 , pp. 491-496
    • Siepmann, M.1    Kleinbloesem, C.2    Kirch, W.3
  • 44
    • 0034082667 scopus 로고    scopus 로고
    • Diltiazem and imbefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone
    • Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and imbefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000; 67: 215-21.
    • (2000) Clin Pharmacol Ther , vol.67 , pp. 215-221
    • Varis, T.1    Backman, J.T.2    Kivisto, K.T.3    Neuvonen, P.J.4
  • 46
    • 0031802051 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients
    • Spoendlin M, Peters J, Welker H, Bock A, Thiel G. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 1998; 13: 1787-91.
    • (1998) Nephrol Dial Transplant , vol.13 , pp. 1787-1791
    • Spoendlin, M.1    Peters, J.2    Welker, H.3    Bock, A.4    Thiel, G.5
  • 49
    • 0033977595 scopus 로고    scopus 로고
    • Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information
    • Muck W. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information. Br J Clin Pharmacol 2000; 49: 87-90.
    • (2000) Br J Clin Pharmacol , vol.49 , pp. 87-90
    • Muck, W.1
  • 50
    • 0036251569 scopus 로고    scopus 로고
    • Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs
    • Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.
    • (2002) Semin Liver Dis , vol.22 , pp. 169-183
    • Chitturi, S.1    George, J.2
  • 51
    • 0030927213 scopus 로고    scopus 로고
    • Protein targets of xenobiotic reactive intermediates
    • Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 1997; 37: 91-117.
    • (1997) Annu Rev Pharmacol Toxicol , vol.37 , pp. 91-117
    • Pumford, N.R.1    Halmes, N.C.2
  • 54
    • 4244183558 scopus 로고    scopus 로고
    • The danger hypothesis - potential role in idiosyncratic drug reactions
    • Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology 2002; 181-182: 55-63.
    • (2002) Toxicology
    • Pirmohamed, M.1    Naisbitt, D.J.2    Gordon, F.3    Park, B.K.4
  • 56
    • 0035996570 scopus 로고    scopus 로고
    • Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system
    • Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367-77.
    • (2002) Curr Drug Metab , vol.3 , pp. 367-377
    • Ju, C.1    Uetrecht, J.P.2
  • 59
    • 0028071759 scopus 로고
    • Noninvasive tests of CYP3A enzymes
    • Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84.
    • (1994) Pharmacogenetics , vol.4 , pp. 171-184
    • Watkins, P.B.1
  • 60
    • 0037374331 scopus 로고    scopus 로고
    • Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity
    • Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199-208.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 199-208
    • Kharasch, E.D.1    Hoffer, C.2    Walker, A.3    Sheffels, P.4
  • 61
    • 0009750846 scopus 로고    scopus 로고
    • Comparative safety of the different macrolides
    • Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18: S71-6.
    • (2001) Int J Antimicrob Agents , vol.18
    • Rubinstein, E.1
  • 62
    • 0029130840 scopus 로고
    • Macrolide antibacterials. Drug interactions of clinical significance
    • von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
    • (1995) Drug Saf , vol.13 , pp. 105-122
    • von Rosensteil, N.A.1    Adam, D.2
  • 63
    • 0033831197 scopus 로고    scopus 로고
    • An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
    • Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-7.
    • (2000) Drug Metab Dispos , vol.28 , pp. 1031-1037
    • Mayhew, B.S.1    Jones, D.R.2    Hall, S.D.3
  • 65
    • 0042634397 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine
    • Hall J, Naranjo CA, Sproule BA, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 2003; 23: 349-57.
    • (2003) J Clin Psychopharmacol , vol.23 , pp. 349-357
    • Hall, J.1    Naranjo, C.A.2    Sproule, B.A.3    Herrmann, N.4
  • 66
  • 67
    • 0028303957 scopus 로고
    • Treatment and prevention of tuberculosis in HIV-infected persons
    • Cohn DL. Treatment and prevention of tuberculosis in HIV-infected persons. Infect Dis Clin North Am 1994; 8: 399-412.
    • (1994) Infect Dis Clin North Am , vol.8 , pp. 399-412
    • Cohn, D.L.1
  • 68
    • 0032710353 scopus 로고    scopus 로고
    • Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis
    • Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999; 13: 2069-74.
    • (1999) AIDS , vol.13 , pp. 2069-2074
    • Gourevitch, M.N.1    Hartel, D.2    Selwyn, P.A.3    Schoenbaum, E.E.4    Klein, R.S.5
  • 69
    • 0035712266 scopus 로고    scopus 로고
    • Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
    • Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 799-804.
    • (2002) Eur J Clin Pharmacol , vol.57 , pp. 799-804
    • Wen, X.1    Wang, J.S.2    Neuvonen, P.J.3    Backman, J.T.4
  • 70
    • 0014310394 scopus 로고
    • Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs
    • Kutt H, Verebely K, McDowell F. Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs. Neurology 1968; 18: 706-10.
    • (1968) Neurology , vol.18 , pp. 706-710
    • Kutt, H.1    Verebely, K.2    McDowell, F.3
  • 71
    • 0018374181 scopus 로고
    • Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston Collaborative Drug Surveillance Program
    • Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston Collaborative Drug Surveillance Program. Chest 1979; 75: 356-8.
    • (1979) Chest , vol.75 , pp. 356-358
    • Miller, R.R.1    Porter, J.2    Greenblatt, D.J.3
  • 73
    • 0025267150 scopus 로고    scopus 로고
    • Samigun, Mulyono, Santoso B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br J Clin Pharmacol 1990; 29: 570-3.
    • Samigun, Mulyono, Santoso B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br J Clin Pharmacol 1990; 29: 570-3.
  • 75
    • 0033863264 scopus 로고    scopus 로고
    • Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro
    • Wandel C, Kim RB, Guengerich FP, Wood AJJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000; 28: 895-8.
    • (2000) Drug Metab Dispos , vol.28 , pp. 895-898
    • Wandel, C.1    Kim, R.B.2    Guengerich, F.P.3    Wood, A.J.J.4
  • 77
    • 0027394348 scopus 로고
    • Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
    • Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45: 384-409.
    • (1993) Drugs , vol.45 , pp. 384-409
    • Brogden, R.N.1    Goa, K.L.2    Faulds, D.3
  • 79
    • 0033061072 scopus 로고    scopus 로고
    • Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)
    • He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288: 791-7.
    • (1999) J Pharmacol Exp Ther , vol.288 , pp. 791-797
    • He, K.1    Woolf, T.F.2    Hollenberg, P.F.3
  • 80
    • 0031931151 scopus 로고    scopus 로고
    • Antiprogestin-mediated inactivation of cytochrome P450 3A4
    • Jang GR, Benet LZ. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology 1998; 56: 150-7.
    • (1998) Pharmacology , vol.56 , pp. 150-157
    • Jang, G.R.1    Benet, L.Z.2
  • 81
    • 2442649042 scopus 로고    scopus 로고
    • Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases
    • Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32: 587-94.
    • (2004) Drug Metab Dispos , vol.32 , pp. 587-594
    • Sridar, C.1    Goosen, T.C.2    Kent, U.M.3    Williams, J.A.4    Hollenberg, P.F.5
  • 82
    • 0031790709 scopus 로고    scopus 로고
    • Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
    • Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26: 552-61.
    • (1998) Drug Metab Dispos , vol.26 , pp. 552-561
    • Koudriakova, T.1    Iatsimirskaia, E.2    Utkin, I.3    Gangl, E.4    Vouros, P.5    Storozhuk, E.6
  • 84
    • 0031751330 scopus 로고    scopus 로고
    • Cinical pharmacokinetics and interactions with other anti-HIV agents
    • Hsu A, Granneman GR, Bertz RJ. Cinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
    • (1998) Clin Pharmacokinet , vol.35 , pp. 275-291
    • Hsu, A.1    Granneman, G.R.2    Bertz, R.J.3
  • 85
    • 7144257182 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
    • Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64.
    • (1998) Clin Pharmacol Ther , vol.63 , pp. 453-464
    • Hsu, A.1    Granneman, G.R.2    Cao, G.3    Carothers, L.4    el-Shourbagy, T.5    Baroldi, P.6
  • 90
    • 0036232065 scopus 로고    scopus 로고
    • The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and down-regulators
    • O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and down-regulators. Lancet Oncol 2002; 3: 207-14.
    • (2002) Lancet Oncol , vol.3 , pp. 207-214
    • O'Regan, R.M.1    Jordan, V.C.2
  • 92
    • 0028208456 scopus 로고
    • Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
    • Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 527-537
    • Fisher, B.1    Costantino, J.P.2    Redmond, C.K.3    Fisher, E.R.4    Wickerham, D.L.5    Cronin, W.M.6
  • 93
    • 0019411776 scopus 로고
    • Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues
    • Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981; 256: 859-68.
    • (1981) J Biol Chem , vol.256 , pp. 859-868
    • Borgna, J.L.1    Rochefort, H.2
  • 94
    • 0036793163 scopus 로고    scopus 로고
    • Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites
    • Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863-78.
    • (2002) Xenobiotica , vol.32 , pp. 863-878
    • Zhao, X.J.1    Jones, D.R.2    Wang, Y.H.3    Grimm, S.W.4    Hall, S.D.5
  • 95
    • 0024507146 scopus 로고
    • Tamoxifen-warfarin interaction: The Aberdeen hospitals drug file
    • Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: The Aberdeen hospitals drug file. BMJ 1989; 298: 1253.
    • (1989) BMJ , vol.298 , pp. 1253
    • Ritchie, L.D.1    Grant, S.M.2
  • 96
    • 0024507312 scopus 로고
    • Life threatening interaction between tamoxifen and warfarin
    • Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989; 298: 93.
    • (1989) BMJ , vol.298 , pp. 93
    • Tenni, P.1    Lalich, D.L.2    Byrne, M.J.3
  • 97
    • 84970843754 scopus 로고
    • Life threatening interaction between tamoxifen and warfarin
    • Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed) 1987; 295: 1141.
    • (1987) Br Med J (Clin Res Ed) , vol.295 , pp. 1141
    • Lodwick, R.1    McConkey, B.2    Brown, A.M.3
  • 99
    • 0027399545 scopus 로고
    • Acetaminophen hepatotoxicity: Potentiation by isoniazid
    • Crippin JS. Acetaminophen hepatotoxicity: Potentiation by isoniazid. Am J Gastroenterol 1993; 88: 590-5.
    • (1993) Am J Gastroenterol , vol.88 , pp. 590-595
    • Crippin, J.S.1
  • 100
    • 0027958433 scopus 로고
    • Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis
    • Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408-11.
    • (1994) Chest , vol.105 , pp. 408-411
    • Nolan, C.M.1    Sandblom, R.E.2    Thummel, K.E.3    Slattery, J.T.4    Nelson, S.D.5
  • 102
    • 36549059303 scopus 로고    scopus 로고
    • Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring
    • Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
    • (2007) Ther Drug Monit , vol.29 , pp. 687-710
    • Zhou, S.F.1    Xue, C.C.2    Yu, X.Q.3    Li, C.4    Wang, G.5
  • 104
    • 0031777718 scopus 로고    scopus 로고
    • Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data an metabolism, together with binding and transport
    • Ito K, Iwatsubo T, Kanamitsu S, Nukajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data an metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998; 38: 461-99.
    • (1998) Annu Rev Pharmacol Toxicol , vol.38 , pp. 461-499
    • Ito, K.1    Iwatsubo, T.2    Kanamitsu, S.3    Nukajima, Y.4    Sugiyama, Y.5
  • 105
    • 0031723235 scopus 로고    scopus 로고
    • Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
    • Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411
    • (1998) Pharmacol Rev , vol.50 , pp. 387-411
    • Ito, K.1    Iwatsubo, T.2    Kanamitsu, S.3    Ueda, K.4    Suzuki, H.5    Sugiyama, Y.6
  • 106
    • 0035064595 scopus 로고    scopus 로고
    • Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data
    • Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 2001; 29: 443-52.
    • (2001) Drug Metab Dispos , vol.29 , pp. 443-452
    • Yamano, K.1    Yamamoto, K.2    Katashima, M.3    Kotaki, H.4    Takedomi, S.5    Matsuo, H.6
  • 108
    • 0027483266 scopus 로고
    • Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats
    • Ohmori S, Ishii I, Kuriya S, Taniguchi T, Rikihisa T, Hirose S, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 1993; 21: 358-63.
    • (1993) Drug Metab Dispos , vol.21 , pp. 358-363
    • Ohmori, S.1    Ishii, I.2    Kuriya, S.3    Taniguchi, T.4    Rikihisa, T.5    Hirose, S.6
  • 110
    • 0032927983 scopus 로고    scopus 로고
    • The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice
    • Tebbe MJ, Jensen CB, Spitzer WA, Franklin RB, George MC, Phillips DL. The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice. Antiviral Res 1999; 42: 25-33.
    • (1999) Antiviral Res , vol.42 , pp. 25-33
    • Tebbe, M.J.1    Jensen, C.B.2    Spitzer, W.A.3    Franklin, R.B.4    George, M.C.5    Phillips, D.L.6
  • 111
    • 0018937071 scopus 로고
    • Self-catalyzed inactivation of hepatic cytochrorne P-450 by ethynyl substrates
    • Ortiz de Montellano PR, Kunze KL. Self-catalyzed inactivation of hepatic cytochrorne P-450 by ethynyl substrates. J Biol Chem 1980; 255: 5578-85.
    • (1980) J Biol Chem , vol.255 , pp. 5578-5585
    • Ortiz de Montellano, P.R.1    Kunze, K.L.2
  • 112
    • 0021345344 scopus 로고
    • Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids
    • Ortiz de Montellano PR, Reich NO. Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J Biol Chem 1994; 259: 4136-41.
    • (1994) J Biol Chem , vol.259 , pp. 4136-4141
    • Ortiz de Montellano, P.R.1    Reich, N.O.2
  • 113
    • 0031717972 scopus 로고    scopus 로고
    • Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
    • Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42: S44-9.
    • (1998) Cancer Chemother Pharmacol , vol.42
    • Sugiyama, Y.1    Kato, Y.2    Chu, X.3
  • 116
    • 0030959378 scopus 로고    scopus 로고
    • Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
    • Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997; 281: 304-14.
    • (1997) J Pharmacol Exp Ther , vol.281 , pp. 304-314
    • Chu, X.Y.1    Kato, Y.2    Niinuma, K.3    Sudo, K.I.4    Hakusui, H.5    Sugiyama, Y.6
  • 117
    • 0037032045 scopus 로고    scopus 로고
    • The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)
    • Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 2002; 16: 1743-7.
    • (2002) AIDS , vol.16 , pp. 1743-1747
    • Olson, D.P.1    Scadden, D.T.2    D'Aquila, R.T.3    De Pasquale, M.P.4
  • 120
    • 0037229942 scopus 로고    scopus 로고
    • Role of P-glycoprotein in pharmacokinetics: Clinical implications
    • Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 2003; 41: 59-98.
    • (2003) Clin Pharmacokinet , vol.41 , pp. 59-98
    • Lin, J.H.1    Yamazaki, M.2
  • 121
    • 0028028123 scopus 로고
    • The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function
    • Lecureur V, Fardel O, Guilouzo A. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 1994; 355: 187-91.
    • (1994) FEBS Lett , vol.355 , pp. 187-191
    • Lecureur, V.1    Fardel, O.2    Guilouzo, A.3
  • 125
    • 0034634252 scopus 로고    scopus 로고
    • Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
    • Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67: 3103-12.
    • (2000) Life Sci , vol.67 , pp. 3103-3112
    • Chan, W.K.1    Delucchi, A.B.2
  • 126
    • 0034089555 scopus 로고    scopus 로고
    • Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
    • Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17: 419-26.
    • (2000) Pharm Res , vol.17 , pp. 419-426
    • Kanamitsu, S.1    Ito, K.2    Green, C.E.3    Tyson, C.A.4    Shimada, N.5    Sugiyama, Y.6
  • 127
    • 10044257558 scopus 로고    scopus 로고
    • Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro
    • Polasek TM, Elliot DJ, Lewis BC, Miners JO. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 2004; 311: 996-1007.
    • (2004) J Pharmacol Exp Ther , vol.311 , pp. 996-1007
    • Polasek, T.M.1    Elliot, D.J.2    Lewis, B.C.3    Miners, J.O.4
  • 130
    • 0036207927 scopus 로고    scopus 로고
    • Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytorhrome P450 enzymes
    • Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytorhrome P450 enzymes. Drug Metab Dispos 2002; 30: 391-6.
    • (2002) Drug Metab Dispos , vol.30 , pp. 391-396
    • Hanioka, N.1    Ozawa, S.2    Jinno, H.3    Tanaka-Kagawa, T.4    Nishimura, T.5    Ando, M.6
  • 131
    • 11844283327 scopus 로고    scopus 로고
    • Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism based
    • Richter T, Schwab M, Eichelbaum M, Zanger UM. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism based. Biochem Pharmacol 2005; 69: 517-24.
    • (2005) Biochem Pharmacol , vol.69 , pp. 517-524
    • Richter, T.1    Schwab, M.2    Eichelbaum, M.3    Zanger, U.M.4
  • 132
    • 0034954153 scopus 로고    scopus 로고
    • A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thio-TEPA and the autoinduction of cyclophosphamide
    • Huitema AD, Mathot RA, Tibben-MM, Rodenhuis S, Beijnen JH. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thio-TEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 2001; 28: 211-30.
    • (2001) J Pharmacokinet Pharmacodyn , vol.28 , pp. 211-230
    • Huitema, A.D.1    Mathot, R.A.2    MM, T.3    Rodenhuis, S.4    Beijnen, J.H.5
  • 133
    • 0033948964 scopus 로고    scopus 로고
    • Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole
    • von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259-61.
    • (2000) Eur J Clin Pharmacol , vol.56 , pp. 259-261
    • von Moltke, L.L.1    Durol, A.L.2    Duan, S.X.3    Greenblatt, D.J.4
  • 134
    • 10744229689 scopus 로고    scopus 로고
    • Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative
    • Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, et al. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 2003; 31: 1170-5.
    • (2003) Drug Metab Dispos , vol.31 , pp. 1170-1175
    • Luo, G.1    Lin, J.2    Fiske, W.D.3    Dai, R.4    Yang, T.J.5    Kim, S.6
  • 135
    • 0029553030 scopus 로고
    • Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor
    • Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275: 1527-34.
    • (1995) J Pharmacol Exp Ther , vol.275 , pp. 1527-1534
    • Chiba, M.1    Nishime, J.A.2    Lin, J.H.3
  • 137
    • 0032706108 scopus 로고    scopus 로고
    • Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes
    • Masubuchi Y, Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 1999; 12: 1028-32.
    • (1999) Chem Res Toxicol , vol.12 , pp. 1028-1032
    • Masubuchi, Y.1    Horie, T.2
  • 138
    • 0034854303 scopus 로고    scopus 로고
    • Inhibitory effects of verapamil and diltiazem on siravastatin metabolism in human liver microsomes
    • Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on siravastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70.
    • (2001) Br J Clin Pharmacol , vol.51 , pp. 461-470
    • Yeo, K.R.1    Yeo, W.W.2
  • 139
    • 0032773854 scopus 로고    scopus 로고
    • Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation
    • Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116-25.
    • (1999) J Pharmacol Exp Ther , vol.290 , pp. 1116-1125
    • Jones, D.R.1    Gorski, J.C.2    Hamman, M.A.3    Mayhew, B.S.4    Rider, S.5    Hall, S.D.6
  • 140
    • 0033959578 scopus 로고    scopus 로고
    • Drug interactions with calcium channel blockers: Possible-involvement of metabolite-intermediate complexation with CYP3A
    • Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: Possible-involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-30.
    • (2000) Drug Metab Dispos , vol.28 , pp. 125-130
    • Ma, B.1    Prueksaritanont, T.2    Lin, J.H.3
  • 141
    • 17844387084 scopus 로고    scopus 로고
    • Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil
    • Wang YH, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 2005; 33: 664-71.
    • (2005) Drug Metab Dispos , vol.33 , pp. 664-671
    • Wang, Y.H.1    Jones, D.R.2    Hall, S.D.3
  • 142
    • 0025184340 scopus 로고
    • Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
    • Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-71.
    • (1990) Chem Res Toxicol , vol.3 , pp. 363-371
    • Guengerich, F.P.1
  • 143
    • 0035996330 scopus 로고    scopus 로고
    • Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation
    • Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, et al. Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 2002; 15: 907-14.
    • (2002) Chem Res Toxicol , vol.15 , pp. 907-914
    • Chen, Q.1    Ngui, J.S.2    Doss, G.A.3    Wang, R.W.4    Cai, X.5    DiNinno, F.P.6
  • 144
    • 0032865554 scopus 로고    scopus 로고
    • Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
    • Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48: 543-52.
    • (1999) Br J Clin Pharmacol , vol.48 , pp. 543-552
    • Eagling, V.A.1    Profit, L.2    Back, D.J.3
  • 145
    • 14644439295 scopus 로고    scopus 로고
    • Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: Mechanism-based inhibition
    • Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci 2005; 76: 2381-91.
    • (2005) Life Sci , vol.76 , pp. 2381-2391
    • Usia, T.1    Watabe, T.2    Kadota, S.3    Tezuka, Y.4
  • 146
    • 0030696487 scopus 로고    scopus 로고
    • Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
    • Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33.
    • (1997) Drug Metab Dispos , vol.25 , pp. 1228-1233
    • Schmiedlin-Ren, P.1    Edwards, D.J.2    Fitzsimmons, M.E.3    He, K.4    Lown, K.S.5    Woster, P.M.6
  • 147
    • 24144432308 scopus 로고    scopus 로고
    • Mechanism-based inactivation of human liver microsomal CYP3A4 by rutae-carpine and limonin from Evodia fruit extract
    • Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutae-carpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005; 20: 34-45.
    • (2005) Drug Metab Pharmacokinet , vol.20 , pp. 34-45
    • Iwata, H.1    Tezuka, Y.2    Kadota, S.3    Hiratsuka, A.4    Watabe, T.5
  • 148
    • 0034889873 scopus 로고    scopus 로고
    • Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein
    • Stupans I, Murray M, Kirlich A, Tuck KL, Hayball PJ. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol 2001; 39: 1119-24.
    • (2001) Food Chem Toxicol , vol.39 , pp. 1119-1124
    • Stupans, I.1    Murray, M.2    Kirlich, A.3    Tuck, K.L.4    Hayball, P.J.5
  • 149
    • 0036785511 scopus 로고    scopus 로고
    • Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine
    • Masubuchi Y, Ose A, Horie T. Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 2002; 30: 1143-8
    • (2002) Drug Metab Dispos , vol.30 , pp. 1143-1148
    • Masubuchi, Y.1    Ose, A.2    Horie, T.3
  • 150
    • 0142181023 scopus 로고    scopus 로고
    • Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components
    • Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31: 1391-7
    • (2003) Drug Metab Dispos , vol.31 , pp. 1391-1397
    • Chatterjee, P.1    Franklin, M.R.2
  • 151
    • 1342310586 scopus 로고    scopus 로고
    • Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol
    • Alvarez-Diez TM, Zheng J. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem Res Toxicol 2004; 17: 150-7.
    • (2004) Chem Res Toxicol , vol.17 , pp. 150-157
    • Alvarez-Diez, T.M.1    Zheng, J.2
  • 152
    • 0033791657 scopus 로고    scopus 로고
    • In vitro evaluation of the disposition of A novel cysteine protease inhibitor
    • Jacobsen W, Christians U, Benet LZ. In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos 2000; 28: 1343-51.
    • (2000) Drug Metab Dispos , vol.28 , pp. 1343-1351
    • Jacobsen, W.1    Christians, U.2    Benet, L.Z.3
  • 153
    • 0037300346 scopus 로고    scopus 로고
    • A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
    • Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, et al. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol 2003; 58: 683-8.
    • (2003) Eur J Clin Pharmacol , vol.58 , pp. 683-688
    • Zdravkovic, M.1    Olsen, A.K.2    Christiansen, T.3    Schulz, R.4    Taub, M.E.5    Thomsen, M.S.6
  • 154
    • 33744975050 scopus 로고    scopus 로고
    • Thienopyridines and statins: Assessing a potential drug-drug interaction
    • Neubauer H, Mugge A. Thienopyridines and statins: Assessing a potential drug-drug interaction. Curr Pharm Des 2006; 12(10): 1271-80.
    • (2006) Curr Pharm Des , vol.12 , Issue.10 , pp. 1271-1280
    • Neubauer, H.1    Mugge, A.2
  • 155
    • 33745002984 scopus 로고    scopus 로고
    • Porcine cytochrome P450 and metabolism
    • Skaanild MT. Porcine cytochrome P450 and metabolism. Curr Pharm Des 2006; 12(11): 1421-7.
    • (2006) Curr Pharm Des , vol.12 , Issue.11 , pp. 1421-1427
    • Skaanild, M.T.1
  • 156
    • 33748745120 scopus 로고    scopus 로고
    • Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles
    • Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 2006; 12(27): 3459-65.
    • (2006) Curr Pharm Des , vol.12 , Issue.27 , pp. 3459-3465
    • Supuran, C.T.1    Mastrolorenzo, A.2    Barbaro, G.3    Scozzafava, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.